


## PHARMACEUTICAL 2017



## Matinas BioPharma Holdings Inc. Rank 147 of 292





## PHARMACEUTICAL 2017



## Matinas BioPharma Holdings Inc. Rank 147 of 292

The relative strengths and weaknesses of Matinas BioPharma Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Matinas BioPharma Holdings Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 80% points. The greatest weakness of Matinas BioPharma Holdings Inc. is the variable Net Income, reducing the Economic Capital Ratio by 39% points.

The company's Economic Capital Ratio, given in the ranking table, is 75%, being 72% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	4,565
Cost of Goods Sold	0
Intangible Assets	1,336
Liabilities, Current	1,445
Liabilities, Non-Current	0
Other Assets	3,558
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	1,222
Other Net Income	658
Other Revenues	0
Property and Equipment	356
Research and Development	3,948
Selling, General and Administrative Expense	4,309

Output Variable	Value in 1000 USD
Assets	9,816
Liabilities	2,666
Expenses	8,257
Revenues	0
Stockholders Equity	7,150
Net Income	-7,599
Comprehensive Net Income	-7,599
Economic Capital Ratio	75%

